Parliament Workbench

Question thread · 8 questions

Whether NHS Quality Improvement Scotland has made any recommendations for any particular drugs not to be used for the treatment of Alzheimer’s Disease on the NHS.

Started with S2W-20285 on 2 Nov 2005; latest 30 Nov 2005. Each later question says it follows up an earlier answer.

Follow-ups
7
longest chain 1 step
Span
28 days
2 Nov 2005 to 30 Nov 2005
Answered
8 of 8
by Andy Kerr
Asked by
1
Alex Neil

The thread, in order

Each answer’s opening lines; open a question for the full text
  1. S2W-20285 2 Nov 2005 Alex Neil SNP Answered

    To ask the Scottish Executive whether NHS Quality Improvement Scotland has made any recommendations for any particular drugs not to be used for the treatment of Alzheimer’s Disease on the NHS.

    Andy Kerr, 10 Nov 2005: The Medicines and Healthcare products Regulatory Agency (MHRA) provides a licence for any given medicine in the UK. This ensures that medicines meet acceptable standards on safety, quality and efficacy. The Scottish Medicines Consortium (SMC) advises NHSScotland on the costs and benefits of new medicines after they ha…
  2. S2W-21266 30 Nov 2005 Alex Neil SNP Answered

    Whether the Medicines and Healthcare products Regulatory Agency is a UK-wide body whose decisions are binding on the Executive and the NHS in Scotland.

    Andy Kerr, 12 Dec 2005: The regulation and safety of medicines is a reserved matter. The Medicines and Healthcare products Regulatory Agency is the government agency which is responsible for ensuring that medicines and medical devices marketed in the UK are acceptably safe. Information about the agency and its work can be found at www.mhra.g…
  3. S2W-21267 30 Nov 2005 Alex Neil SNP Answered follows S2W-20285

    Why NHS Quality Improvement Scotland is awaiting the final recommendation of the National Institute for Clinical Excellence in relation to its consultation document, Alzheimer’s disease – donepezil, rivastigmine, galantamine and memantine, when NHS Quality Improvement Scotland is responsible for making recommendations in respect of the use of these drugs within the NHS in Scotland.

    Andy Kerr, 12 Dec 2005: NHS Quality Improvement Scotland (NHS QIS) has published comments on all NICE appraisals since May 2001. It does not re-assess the evidence used by NICE to avoid duplication of effort and to ensure public resources are used effectively and efficiently. NHS QIS considers possible differences in the application of appra…
  4. S2W-21268 30 Nov 2005 Alex Neil SNP Answered follows S2W-20285

    Why the Scottish Medicines Consortium does not recommend that Memantine (Exiba ®) is used to treat moderately severe to severe Alzheimer’s Disease and whether this indicates that the drug is used to treat milder cases of Alzheimer’s Disease.

    Andy Kerr, 12 Dec 2005: The Scottish Medicines Consortium (SMC) reviewed memantine (Ebixa) in July 2003 and did not recommend it for use within NHS Scotland. Its advice was that, although this is currently the only agent licensed for use in moderately severe to severe Alzheimer's disease, the magnitude of the effect is extremely small. Compa…
  5. S2W-21269 30 Nov 2005 Alex Neil SNP Answered follows S2W-20285

    What the relationship is between the Scottish Medicines Consortium and NHS Quality Improvement Scotland.

    Andy Kerr, 12 Dec 2005: I refer the member to the answer given to S2W-21270, answered on 12 December 2005. All answers to written parliamentary questions are available on the Parliament's website, the search facility for which can be found at: http://www.scottish.parliament.uk/webapp/wa.search.
  6. S2W-21270 30 Nov 2005 Alex Neil SNP Answered follows S2W-20285

    And if it is the responsibility of the Scottish Medicines Corsortium to advise the NHS on the suitability of medicines, why it is the responsibility of NHS Quality Improvement Scotland to advise NHS Scotland on the implications of the guidance from the National Institute for Clinical Excellence resulting from its consultation document, Alzheimer’s disease – donepezil, rivastigmine, galantamine and memantine.

    Andy Kerr, 12 Dec 2005: The Scottish Medicines Consortium (SMC) advises NHSScotland on the clinical and cost effectiveness of all new medicines, formulations and indications at, or as soon as possible after, the time of launch of a medicine. National Institute for Health and Clinical Excellence (NICE) appraisals (multiple technology appraisa…
  7. S2W-21271 30 Nov 2005 Alex Neil SNP Answered follows S2W-20285

    Whether the decisions of the Medicines and Healthcare products Regulatory Agency or the European Medicines Agency are binding on the Executive and the NHS in Scotland.

    Andy Kerr, 12 Dec 2005: Before a medicine can be placed on the UK market it must have a marketing authorisation either from the Medicines and Healthcare products Regulatory Agency or the European Medicines Agency. Decisions on the marketing authorisations of medicines made by the MHRA or the EMEA are binding on the Executive and the NHS in S…
  8. S2W-21272 30 Nov 2005 Alex Neil SNP Answered follows S2W-20285

    Whether there have been any instances where the Scottish Medicines Consortium has made a recommendation on the use of a drug to NHS Scotland but has been subsequently contradicted by the National Institute for Health and Clinical Excellence’s advice to the NHS in England and Wales which has then been implemented in Scotland and, if so, whether it will provide details of such instances.

    Andy Kerr, 12 Dec 2005: The Scottish Medicines Consortium (SMC) reviewed Pimecrolimus cream (ElidelÒ) in July 2004, and did not recommend it for use. SMC advice was: “Pimecrolimus cream is the first topical immunomodulator licensed for the treatment of signs and symptoms of mild-to-moderate atopic dermatitis. There is no evidence that it has…

How this thread is put together

Follow-up
A question whose text says it is “further to the answer to question …” (or reply, response, or asks for a “substantive answer” to an earlier question). The question it names is its parent.
Several citations
When a question cites more than one earlier question, the most recent one we hold is used as the parent; the others are listed as “also cites”.
Thread
Follow parents back to the first question; every question that leads back to it is in this thread. Branches are shown in date order.

All question threads